News

Mexico backs marketing of Aegerion’s Juxtapid for HoFH

Mexico backs marketing of Aegerion’s Juxtapid for HoFH

20-01-2014

US emerging biotech firm Aegerion Pharmaceuticals says that the Mexican Federal Commission for the Protection…

Aegerion PharmaceuticalsJuxtapidMexicoPharmaceuticalRare diseasesRegulationSouth America

Aegerion receives US subpoena over USA sales of Juxtapid

Aegerion receives US subpoena over USA sales of Juxtapid

13-01-2014

US biopharma company Aegerion Pharmaceuticals has received a subpoena from the US Department of Justice…

Aegerion PharmaceuticalsFinancialJuxtapidLegalPharmaceuticalRare diseasesUSA

Aegerion gains European approval for rare disease drug

05-08-2013

The European Commission has approved US biopharma company Aegerion Pharmaceuticals' (Nasdaq: AEGR) Lojuxta…

Aegerion PharmaceuticalsBiotechnologyCardio-vascularEuropeJuxtapidKynamroLojuxtalomitapidePharmaceuticalRare diseasesRegulation

Further batch of positive EMA/CHMP opinions for Bavarian Nordic, Aegerion, Teva and CSL Behring

31-05-2013

Following its May meetings, the European Medicines Agency's European Committee for Medicinal Products…

Aegerion PharmaceuticalsBavarian NordicCSL BehringEuropeImvanexLojuxtaLonquexOncologyPharmaceuticalRegulationTeva Pharmaceutical IndustriesVaccinesVoncento

US FDA approves ThromboGenics' Jetrea; advisory backing for Aegerion's lomitapide

19-10-2012

Belgian drugmaker ThromboGenics NV (Euronext Brussels: THR) yesterday received US Food and Drug Administration…

Aegerion PharmaceuticalsCardio-vascularJetrealomitapideNorth AmericaOphthalmicsPharmaceuticalRegulationThromboGenics

COMPANY SPOTLIGHT

Menarini

Back to top